Dr. Taimur Sher, MD
What this data tells you about Dr. Sher
Dr. Taimur Sher is a hematology & oncology in Jacksonville, FL, with 16 years in practice. Based on federal Medicare data, Dr. Sher performed 51,153 Medicare services across 2,020 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sher received a total of $10,179 from 6 pharmaceutical and/or device companies across 25 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sher is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 9,202 | $40 | $195 |
| Filgrastim injection (Nivestym) for white blood cells | 8,640 | $0 | $1 |
| Nivolumab injection (Opdivo) | 6,860 | $24 | $112 |
| Daratumumab injection (Darzalex) | 4,860 | $38 | $189 |
| Darbepoetin injection (Aranesp) for anemia | 4,780 | $2 | $11 |
| Anti-nausea injection (fosaprepitant) | 4,350 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 2,100 | $18 | $89 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,565 | $24 | $185 |
| Dexamethasone injection (steroid) | 1,144 | $0 | $4 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,110 | $22 | $196 |
| Anti-nausea injection (ondansetron/Zofran) | 1,048 | $0 | $5 |
| Immune globulin infusion (Gammagard) | 910 | $36 | $137 |
| Injection, bortezomib, 0.1 mg | 833 | $5 | $9 |
| Injection, atropine sulfate, 0.01 mg | 550 | $0 | $1 |
| Injection of additional new drug or substance into vein | 295 | $12 | $216 |
| Administration of chemotherapy into vein, 1 hour or less | 225 | $99 | $869 |
| Anti-nausea injection (Aloxi/palonosetron) | 200 | $1 | $9 |
| Injection, leucovorin calcium, per 50 mg | 194 | $3 | $21 |
| Office visit, established patient (30-39 min) | 192 | $94 | $450 |
| Injection, fluorouracil, 500 mg | 175 | $2 | $25 |
| Office visit, established patient (20-29 min) | 156 | $63 | $296 |
| Hospital follow-up visit, low complexity | 132 | $40 | $175 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 132 | $87 | $449 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 131 | $3 | $34 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 125 | $131 | $487 |
| Injection, carboplatin, 50 mg | 105 | $2 | $29 |
| Collection of blood sample from implanted device | 102 | $19 | $135 |
| Drug injection, under skin or into muscle | 100 | $11 | $102 |
| Infusion, normal saline solution , 1000 cc | 68 | $2 | $82 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 62 | $22 | $233 |
| Administration of chemotherapy into vein, each additional hour | 61 | $22 | $212 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 60 | $26 | $200 |
| Injection, magnesium sulfate, per 500 mg | 60 | $1 | $20 |
| Infusion into a vein for hydration, each additional hour | 58 | $10 | $114 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 57 | $54 | $352 |
| Administration of additional new drug or substance into vein, 1 hour or less | 55 | $50 | $446 |
| Injection, zoledronic acid, 1 mg | 51 | $7 | $50 |
| Injection, diphenhydramine hcl, up to 50 mg | 45 | $1 | $37 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 43 | $49 | $426 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 40 | $16 | $154 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 32 | $133 | $993 |
| Administration of additional new drug or substance into vein using push technique | 30 | $43 | $370 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 29 | $15 | $143 |
| New patient office visit (45-59 min) | 26 | $114 | $707 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 26 | $1 | $80 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $66 | $247 |
| Infusion into a vein for hydration, 31-60 minutes | 22 | $23 | $345 |
| Office visit, established patient, complex (40-54 min) | 18 | $127 | $604 |
| Hospital discharge day management, 30 minutes or less | 16 | $65 | $348 |
| New patient office visit (30-44 min) | 15 | $84 | $456 |
| New patient office visit, complex (60-74 min) | 15 | $175 | $891 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 13 | $68 | $603 |
| Injection of drug or substance into vein | 12 | $27 | $600 |
Industry Payment Transparency
Open Payments through 2021 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2021)
Associated products mentioned in payments ›
The majority of payments (83%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2021 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Sher is a mixed practice specialist, with above-average Medicare volume (top 16% in FL), and consulting-driven industry engagement, with 16 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Sher experienced with pembrolizumab injection (keytruda)?
Does Dr. Sher receive payments from pharmaceutical companies?
How do Dr. Sher's costs compare to other hematology & oncologys in Jacksonville?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology